Published in Pharma Investments, Ventures and Law Weekly, July 17th, 2005
The audited results for the Transition Period are compared with the unaudited results of corresponding period January 1, 2004 - March 31, 2004. A Form 10-K/T will be filed with the SEC for the Transition Period.
Net sales for the Transition Period rose 27% to a record $17.3 million from $13.6 million for the corresponding period of 2004. Gross profit for the Transition Period increased to $9.5 million, from $8.2 million for the corresponding period of 2004, up 16%.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.